Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia

Blood

Volumn 103, Issue 10, 2004, Pages 3644-3654

  Kindler, Thomas ^b   Breitenbuecher, Frank ^b   Marx, Andreas ^b   Beck, Joachim ^b   Hess, Georg ^b   Weinkauf, Birgit ^b   Duyster, Justus ^b   Peschel, Christian ^b   Kirkpatrick, Charles J ^b   Theobald, Matthias ^b   Gschaidmeier, Harald ^b   Huber, Christoph ^b   Fischer, Thomas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYTARABINE; ETOPOSIDE; IMATINIB; MITOXANTRONE; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; ASCITES; BLAST CELL; BLOOD; BLOOD TOXICITY; BONE MARROW; CANCER CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIZZINESS; DNA SEQUENCE; DRUG EFFICACY; DRUG SAFETY; EDEMA; EXON; FEMALE; GENE MUTATION; HEADACHE; HEPATOMEGALY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING; WESTERN BLOTTING;

EID: 2342518106     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-06-2071     Document Type: Article

References (73)

1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051-1062.
2. Appelbaum F, Rowe J, Radich J, Dick J. Acute Myeloid Leukemia, Hematology 2001, American Society of Hematology, Education Program Book: 62-66.
3. Hiddemann W, Kem W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17:3569-3576.
4. Tallman M. Therapy of acute myeloid leukemia. Cancer Control. 2001;8:62-78.
5. Rowe JM, Andersen JW, Cassileth PA, et al. Clinical trials in adults with acute myelogenous leukemia: experience of the Eastern Cooperative Oncology Group. In: Acute Leukemia IV. Experimental Approaches and Novel Therapies. Berlin: Springer Verlag; 1994:541-546.
6. Bennet JM, Young ML, Andersen JW, et al. Long-term survival in acute myeloid leukemia. Cancer. 1997;80:2205-2209.
7. Brincker H. Estimate of overall treatment results in acute nonlymphocytic leukemia based on age-specific rates of incidence and of complete remission. Cancer Treat Rep. 1985;69:5-11.
8. Cartwright RA, Staines A. Acute leukemias. In: Fleming AT, ed. Epidemiology of Hematological Disease, Part I. Baillière's Clin Haematol. 1992; 5:1-26.
9. Keating MJ, Kantarjian H, Smith TL, et al. Response to salvage therapy and survival after relapse in acute myelogenous leukemia. J Clin Oncol. 1989;7:1071-1080.
10. Hiddemann W, Martin W-R, Sauerland C-M, Heinecke A, Büchner T. Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia. 1990;4:164-188.
11. Davis CL, Rohatiner AZS, Lim J, et al. The management of recurrent acute myelogenous leukemia at a single center over a fifteen-year period. Br J Haematol. 1993;83:404-411.
12. Carella AM, Carlier P, Pungolino E, et al. Idarubicin in combination with immediate-dose cytarabine and VP-16 in the treatment of refractory or rapidly relapsed patients with acute myeloid leukemia. Leukemia. 1993;7:196-199.
13. Vignetti M, Orsini E, Petti MC, et al. Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: a single center experience. Ann Oncol. 1996;7:933-938.
14. Welborn JL, Kopecky KJ, Meyers FJ, et al. Carboplatin infusion in relapsed and refractory acute myeloid leukemia - a Southwest Oncology Group trial. Leukemia. 1995;9:1126-1129.
15. Thalhammer F, Geissler K, Jäger U, et al. Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study. Ann Hematol. 1999;72:216-222.
16. Stockerl-Goldstein KE, Blume KG. Allogeneic hematopoietic cell transplantation for adult patients with acute myeloid leukemia. In: Forman SJ, Blume KG, Thomas ED, eds. Hematopoietic Cell Transplantation, vol. 2. Boston, MA: Blackwell Science; 1999:823-834.
17. Scandura JM, Boccuni P, Cammenga J, Nimer SD. Transcription factor fusions in acute leukemia: variations on a theme. Oncogene. 2002;21: 3422-3444.
18. Gilliland DG, Griffin JD. Role of FLT3 in leukemia. Curr Opin Hematol. 2002;9:274-281.
19. Sekeres MA, Stone RM. The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol. 2002;14:24-30.
20. Buchner T, Hiddemann W, Berdel W, et al. Acute myeloid leukemia: treatment over 60. Rev Clin Exp Hematol. 2002;6:46-59.
21. Hiddemann W, Buchner T. Current status and perspectives of therapy for acute myeloid leukemia. Semin Hematol. 2001;38(3 Suppl 6):3-9.
22. Estey EH. How I treat older patients with AML. Blood. 2000;96:1670-1673.
23. Visani G, Bernasconi P, Boni M, et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia-analysis of 848 patients. Leukemia. 2001;15:903-909.
24. Ikeda H, Kanakura Y, Tamaki T, et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 1991; 78:2962-2968.
25. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol. 1999;31:1053-1074.
26. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
27. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol. 1999;154:53-60.
28. Lux ML, Rubin BP, Biase TL, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 2000;156:791-795.
29. Hibi K, Takahashi T, Sekido Y, et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene. 1991;6:2291-2296.
30. Sekido Y, Obata Y, Ueda R, et al. Preferential expression of c-kit protooncogene transcripts in small call lung cancer. Cancer Res. 1991;51: 2416-2419.
31. Sekido Y, Takahashi T, Ueda R, et al. Recombinant human stem cell factor mediates chemotaxis of small-cell lung cancer cell lines aberrantly expressing the c-kit protooncogene. Cancer Res. 1993;53:1709-1714.
32. Rygaard K, Nakamura T, Spang-Thomsen M. Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem call factor, in SCLC cell lines and xenografts. Br J Cancer. 1993;67:37-46.
33. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res. 1996;56:370-376.
34. Hines SJ, Organ C, Komstein MJ, Krystal GW. Coexpression of the c-kit and stem cell factor genes in breast carcinomas. Cell Growth Differ. 1995;6:769-779.
35. Wang C, Curtis JE, Geissler EN, et al. The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia. Leukemia. 1969;3:699-702.
36. Broudy VC, Smith FO, Lin N, Zsebo KM, Egrie J, Bemstein ID. Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. Blood. 1992;80:60-67.
37. Kanakura Y, Ikeda H, Kitayama H, Sugahara H, Furitsu T. Expression, function and activation of the proto-oncogene c-kit product in human leukemia cells. Leuk Lymphoma. 1993;10:35-41.
38. Longley BJ, Reguera MJ, Ma Y. Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy. Leuk Res. 2001;25:571-576.
39. Court EL, Davidson K, Smith MA, et al. C-kit mutation screening in patients with acute myeloid leukemia: adaptation of a Giemsa-stained bone-marrow smear DNA extraction technique. Br J Biomed Sci. 2001;58:76-84.
40. Smolich BD, Yuen HA, West KA, Giles FJ, Albitar GA, Cherrington JM. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid cell line and in acute myeloid leukemia blasts. Blood. 2001;97:1413-1421.
41. Mesters RM, Padro T, Bieker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia. Blood. 2001; 98:241-243.
42. Kindler T, Breitenbuecher F, Marx A, et al. Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesytate in a patient with refractory, secondary AML. Blood. 2003;101:2960-2962.
43. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
44. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
45. Talpaz M, Silver RT, Druker BJ, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99:1928-1937.
46. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal cells. Science. 2003;299:706-710.
47. Remmele W, Stegner HE. [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe. 1987;6:136-140.
48. Kindler T, Breitenbuecher F, Kasper S, et al. In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C. Leukemia. 2003;17:999-1009.
49. Spritz RA, Giebel LB, Holmes SA. Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) protooncogene in human piebaldism. Am J Hum Genet. 1992;50:261-269.
50. Lowenberg B, van Putten WL, Ferrant A, et al. Peripheral blood progenitor cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia. Stem Cells. 1997;15(Suppl 1):177-180.
51. Reckmann AH, Fischer T, Peng B, et al. Effect of food on STI-671 (Glivec) pharmacokinetics and bioavailability [abstract]. J Clin Oncol. 2001; 20(suppl):1223.
52. Gari M, Goodeva A, Wilson G, et al. c-kit protooncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukemia. Br J Haematol. 1999;105:694-900.
53. Beghini A, Manani I, Ripamonti CB, Larizza L. Amplification of a novel c-Kit activating mutation Asn(622)-Lys in the Kasumi-1 cell line: a t(6;21)-Kit mutant model for acute myeloid leukemia. Hematol J. 2002;3:157-163.
54. Riva P, Larizza L. A novel potentially diagnostic polymorphism (4894 A/C) in exon 10 of the human c-kit proto-oncogene. Mol Cell Probes. 1996; 10:387-388.
55. Piao X, Curits JE, Minkin S, Minden MD, Bemstein A. Expression of the Kit and KitA receptor isoforms in human acute myelogenous leukemia. Blood. 1994;83:476-481.
56. Crosier PS, Ricciardi ST, Hall LR, Vitas MR, Clark SC, Crosier KE. Expression of isoforms of the human receptor tyrosine kinase c-kit in leukemic cell lines and acute myeloid leukemia. Blood. 1993;82:1151-1158.
57. Caruana G, Cambareri AC, Ashman LK. Isoforms of c-kit differ in activation of signaling pathways and transformation of NIH3T3 fibroblasts. Oncogene. 1999;18:5573-5581.
58. Voytyuk O Lannartsson J, Mogi A, et al. Src family kinases are involved in the differential signaling from two splice forms of c-kit. J Biol Chem. 2003;278:9159-9166.
59. Cortes J, Giles F, O'Brien S, et al. Results of imatinib mesylate therapy in patients with refractory recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer. 2003;97:2760-2766.
60. Sawyers CL, Hochhaus A, Feldman E, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99:3530-3539.
61. Sawyers CI, Hochhaus A, Feldman EJ, et al. Imatinib (Gleevec, STI571) in patients with chronic myeloid leukemia in myeloid blast crisis (CMC-BC): up to 36 months follow-up of a phase II study [abstract]. Blood, 2002,100:163a.
62. Yildirim Z, Gant BW, Liu XS, et al. Remission in a patient with c-kit positive refractory acute myelogenous leukemia after imatinib treatment [abstract]. Blood. 2002;100:266b.
63. Mohr M, Kratz-Albers K, Oenaldi-Mohr D, Buechner T, Berdel WE, Serve H. Treatment of relapsed acute myeloid leukemia with imatinib [abstract]. Onkologie. 2002;25(Suppl 4):19.
64. von Bubnoff N, Sandherr M, Schwarz K, et al. Acute myeloid leukemia (AML) after hypereosinophilic syndrome with response to imatinib mesylate (Glivec): possible molecular mechanism [abstract]. Onkologie. 2002;25(Suppl 4):23.
65. Schnittheim M, Aichele O, Brümmendorf T, Kranz L, Denzlinger C. Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571) [abstract]. Onkologie. 2002;25(Suppl 4):21.
66. Pietsch T, Kyas U, Steffens U, et al. Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: heterogeneity in response and synergy with other hematopoietic growth factors. Blood. 1992;80:1199-1206.
67. Blair A, Sutherland HJ. Primitive acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo lack surface expression of c-kit (CD117). Exp Hematol. 2000;28:660-671.
68. Clark BR, Keating A. Biology of bone marrow stroma. Ann N Y Acad Sci. 1995;29;770:70-78.
69. Bendall LJ, Daniel A, Kortiepel K, Gottlieb DJ. Bone marrow adherent layers inhibit apoptosis of acute myeloid leukemia cells. Exp Hematol. 1994;22:1252-1260.
70. Garrido SM, Appelbaum FR, Willman CL, Banker DE. Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol. 2001;29:448-457.
71. Fortney JE, Zhao W, Wenger SL, Gibson LF. Bone marrow stromal cells regulate caspase 3 activity in leukemic cells during chemotherapy. Leuk Res. 2001;10:901-907.
72. Weimar IS, Voermans C, Bourhis JH, et al. Hepatocyte growth factor/scatter factor (HGF/SF) affects proliferation and migration of myeloid leukemic cells. Leukemia. 1998;12:1195-1203.
73. Mohle R, Schittenheim M, Failenschmid C, et al. Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 In acute myelomonocytic and lymphoblastic leukemia. Br J Haematol. 2000;110:563-572.